# Norry-Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/norry-biotech

- Industry: Pharmaceuticals
- Headquarters: Wuxi, China
- Website: www.norroybioscience.com
- Latest round: Series A (Feb 28, 2026)
- Investors on record: 1

## About

Based in Wuxi, China, and established in 2021, Wuxi Norry Pharmaceutical Technololy Co., Ltd, trading as Norry-Biotech, is a new drugs R&D company that focuses on the R&D of radiopharmaceuticals, with a research and development team consisting of more than 60 talents. The company and the affiliated Hospital of Jiangnan University have co-established an R&D platform. The firm has established partnerships with SIMN, Sumgen, Doer Biologics, etc. In February 2028, Norry-Biotech raised a series A+ funding from Xinghua Dingli Capital.
The company engages in the R&D of radiopharmaceuticals and has completed multiple target screening and development, including pancreatic, kidney, stomach, ovarian, and prostate cancer. It has developed the clinical translation platform, nuclear drug GMP production platform, fast screening ARC platform, and cloud-based imaging platform and provides automated solutions for the nuclear pharmaceutical industry, from nuclide purification, nuclear drug development/production, nuclear drug dispensing, injection, etc.
The company's revenue is generated by providing radiopharmaceuticals.
Norry-Biotech will use series A+ financing to accelerate the research and development of nuclear medicine products, further meeting the clinical needs in major disease areas such as kidney cancer and gastric cancer.

## Funding rounds

- Series A, Feb 28, 2026 — Xinghua Dingli Capital

## Investors

- Xinghua Dingli Capital (https://capitalatlas.ai/funds/xinghua-dingli-capital) — Series A